Cargando…

Augmented expression of Polo-like kinase 1 is a strong predictor of shorter cancer-specific overall survival in early stage breast cancer at 15-year follow-up

Polo-like kinase 1 (PLK1) is a serine-threonine kinase that plays a crucial role in the regulation of cell division. In addition, it acts as a modulator of the DNA damage response and as a novel factor in the maintenance of genome stability during DNA replication. The present study aimed to reveal t...

Descripción completa

Detalles Bibliográficos
Autores principales: Donizy, Piotr, Halon, Agnieszka, Surowiak, Pawel, Kaczorowski, Maciej, Kozyra, Cyprian, Matkowski, Rafal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4998224/
https://www.ncbi.nlm.nih.gov/pubmed/27602103
http://dx.doi.org/10.3892/ol.2016.4890
_version_ 1782449896758968320
author Donizy, Piotr
Halon, Agnieszka
Surowiak, Pawel
Kaczorowski, Maciej
Kozyra, Cyprian
Matkowski, Rafal
author_facet Donizy, Piotr
Halon, Agnieszka
Surowiak, Pawel
Kaczorowski, Maciej
Kozyra, Cyprian
Matkowski, Rafal
author_sort Donizy, Piotr
collection PubMed
description Polo-like kinase 1 (PLK1) is a serine-threonine kinase that plays a crucial role in the regulation of cell division. In addition, it acts as a modulator of the DNA damage response and as a novel factor in the maintenance of genome stability during DNA replication. The present study aimed to reveal the associations between PLK1 expression and clinicopathological features of patients with breast cancer (BC), particularly patient survival at 5-, 10- and 15-year follow-up. PLK1 expression was evaluated immunohistochemically in routine diagnostic tissue specimens from 83 patients treated radically for stage II BC. Kaplan-Meier analysis revealed a correlation between PLK1 overexpression and long-term survival. High PLK1 immunoreactivity was associated with shorter cancer-specific overall survival (CSOS) and disease-free survival (P=0.00001 and 0.00013, respectively). Multivariate analysis confirmed the negative prognostic significance of PLK1 overexpression for CSOS in all 83 patients (P=0.00030). Furthermore, analogous correlations were observed in both subgroups with and without nodal metastases (P=0.01400 and 0.01200, respectively). The present results indicate that PLK1 expression has a prognostic role in early BC. Immunohistochemical assessment of PLK1 reactivity may potentially become a qualifier for inclusion of PLK1 inhibitor therapy.
format Online
Article
Text
id pubmed-4998224
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-49982242016-09-06 Augmented expression of Polo-like kinase 1 is a strong predictor of shorter cancer-specific overall survival in early stage breast cancer at 15-year follow-up Donizy, Piotr Halon, Agnieszka Surowiak, Pawel Kaczorowski, Maciej Kozyra, Cyprian Matkowski, Rafal Oncol Lett Articles Polo-like kinase 1 (PLK1) is a serine-threonine kinase that plays a crucial role in the regulation of cell division. In addition, it acts as a modulator of the DNA damage response and as a novel factor in the maintenance of genome stability during DNA replication. The present study aimed to reveal the associations between PLK1 expression and clinicopathological features of patients with breast cancer (BC), particularly patient survival at 5-, 10- and 15-year follow-up. PLK1 expression was evaluated immunohistochemically in routine diagnostic tissue specimens from 83 patients treated radically for stage II BC. Kaplan-Meier analysis revealed a correlation between PLK1 overexpression and long-term survival. High PLK1 immunoreactivity was associated with shorter cancer-specific overall survival (CSOS) and disease-free survival (P=0.00001 and 0.00013, respectively). Multivariate analysis confirmed the negative prognostic significance of PLK1 overexpression for CSOS in all 83 patients (P=0.00030). Furthermore, analogous correlations were observed in both subgroups with and without nodal metastases (P=0.01400 and 0.01200, respectively). The present results indicate that PLK1 expression has a prognostic role in early BC. Immunohistochemical assessment of PLK1 reactivity may potentially become a qualifier for inclusion of PLK1 inhibitor therapy. D.A. Spandidos 2016-09 2016-07-20 /pmc/articles/PMC4998224/ /pubmed/27602103 http://dx.doi.org/10.3892/ol.2016.4890 Text en Copyright: © Donizy et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Donizy, Piotr
Halon, Agnieszka
Surowiak, Pawel
Kaczorowski, Maciej
Kozyra, Cyprian
Matkowski, Rafal
Augmented expression of Polo-like kinase 1 is a strong predictor of shorter cancer-specific overall survival in early stage breast cancer at 15-year follow-up
title Augmented expression of Polo-like kinase 1 is a strong predictor of shorter cancer-specific overall survival in early stage breast cancer at 15-year follow-up
title_full Augmented expression of Polo-like kinase 1 is a strong predictor of shorter cancer-specific overall survival in early stage breast cancer at 15-year follow-up
title_fullStr Augmented expression of Polo-like kinase 1 is a strong predictor of shorter cancer-specific overall survival in early stage breast cancer at 15-year follow-up
title_full_unstemmed Augmented expression of Polo-like kinase 1 is a strong predictor of shorter cancer-specific overall survival in early stage breast cancer at 15-year follow-up
title_short Augmented expression of Polo-like kinase 1 is a strong predictor of shorter cancer-specific overall survival in early stage breast cancer at 15-year follow-up
title_sort augmented expression of polo-like kinase 1 is a strong predictor of shorter cancer-specific overall survival in early stage breast cancer at 15-year follow-up
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4998224/
https://www.ncbi.nlm.nih.gov/pubmed/27602103
http://dx.doi.org/10.3892/ol.2016.4890
work_keys_str_mv AT donizypiotr augmentedexpressionofpololikekinase1isastrongpredictorofshortercancerspecificoverallsurvivalinearlystagebreastcancerat15yearfollowup
AT halonagnieszka augmentedexpressionofpololikekinase1isastrongpredictorofshortercancerspecificoverallsurvivalinearlystagebreastcancerat15yearfollowup
AT surowiakpawel augmentedexpressionofpololikekinase1isastrongpredictorofshortercancerspecificoverallsurvivalinearlystagebreastcancerat15yearfollowup
AT kaczorowskimaciej augmentedexpressionofpololikekinase1isastrongpredictorofshortercancerspecificoverallsurvivalinearlystagebreastcancerat15yearfollowup
AT kozyracyprian augmentedexpressionofpololikekinase1isastrongpredictorofshortercancerspecificoverallsurvivalinearlystagebreastcancerat15yearfollowup
AT matkowskirafal augmentedexpressionofpololikekinase1isastrongpredictorofshortercancerspecificoverallsurvivalinearlystagebreastcancerat15yearfollowup